Nanotechnology-enhanced immunotherapy for metastatic cancer

Simple item page
dc.citation.articleNumber100174
dc.citation.issueNumber4
dc.citation.journalTitleThe Innovation
dc.citation.volumeNumber2
dc.contributor.authorZhang, Peisen
dc.contributor.authorMeng, Junli
dc.contributor.authorLi, Yingying
dc.contributor.authorYang, Chen
dc.contributor.authorHou, Yi
dc.contributor.authorTang, Wen
dc.contributor.authorMcHugh, Kevin J.
dc.contributor.authorJing, Lihong
dc.date.accessioned2021-12-02T15:09:17Z
dc.date.available2021-12-02T15:09:17Z
dc.date.issued2021
dc.description.abstractA vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective treatments for metastases are currently lacking due to the difficulty of selectively targeting these small, delocalized tumors distributed across a variety of organs. However, nanotechnology holds tremendous promise for improving immunotherapeutic outcomes in patients with metastatic cancer. In contrast to conventional cancer immunotherapies, rationally designed nanomaterials can trigger specific tumoricidal effects, thereby improving immune cell access to major sites of metastasis such as bone, lungs, and lymph nodes, optimizing antigen presentation, and inducing a persistent immune response. This paper reviews the cutting-edge trends in nano-immunoengineering for metastatic cancers with an emphasis on different nano-immunotherapeutic strategies. Specifically, it discusses directly reversing the immunological status of the primary tumor, harnessing the potential of peripheral immune cells, preventing the formation of a pre-metastatic niche, and inhibiting the tumor recurrence through postoperative immunotherapy. Finally, we describe the challenges facing the integration of nanoscale immunomodulators and provide a forward-looking perspective on the innovative nanotechnology-based tools that may ultimately prove effective at eradicating metastatic diseases.
dc.identifier.citationZhang, Peisen, Meng, Junli, Li, Yingying, et al.. "Nanotechnology-enhanced immunotherapy for metastatic cancer." <i>The Innovation,</i> 2, no. 4 (2021) Elsevier: https://doi.org/10.1016/j.xinn.2021.100174.
dc.identifier.digital1-s2-0-S2666675821000990-main
dc.identifier.doihttps://doi.org/10.1016/j.xinn.2021.100174
dc.identifier.urihttps://hdl.handle.net/1911/111710
dc.language.isoeng
dc.publisherElsevier
dc.rightsThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.titleNanotechnology-enhanced immunotherapy for metastatic cancer
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpublisher version
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2-0-S2666675821000990-main.pdf
Size:
7.69 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Bioengineering Publications